Lilly stockpiles about $550 million of its unapproved obesity pill

Eli Lilly disclosed in a regulatory filing that it had built up close to $548 million in "pre-launch inventory" of its experimental oral obesity drug, orforglipron, and related materials, according to a filing reported on February 20, 2025 ^[1][2]. The disclosure came more than a year before the drug was expected to reach the market, an unusually early and large inventory build for a medicine that had not yet finished late-stage testing ^[1].

Most drugmakers record pre-launch inventory to show how much product they have manufactured right before a regulatory approval. Kevin Gade, chief operating officer at Bahl & Gaynor, an investor in Lilly shares, said this build is different: it is happening well ahead of an expected 2026 launch and is "certainly much larger than normal" compared with other examples, such as inventory built for COVID-19 vaccines ^[1]. Gade said the move reflects Lilly's desire to launch as early as possible and build a time advantage over rivals ^[1].

Evercore ISI analyst Umer Raffat, who flagged the inventory build in a research note, said the so-called capitalized inventory implied roughly $10 billion in sales based on 2024 figures alone, and said the build-up would likely keep growing ^[1]. Lilly also told investors on its February 2025 earnings call that it was already expanding manufacturing capacity for the drug ^[1].

The bet is grounded in trial data. In a mid-stage study, the highest dose of orforglipron produced 14.7% weight loss after 36 weeks in people who were overweight or had obesity ^[1]. Lilly was expected to report late-stage trial results by April 2025 ^[1]. At the time of the filing, orforglipron had not yet been approved by regulators ^[1][2].

Why it matters for patients

For people who inject tirzepatide (Mounjaro or Zepbound) or semaglutide (Ozempic, Wegovy, Rybelsus) today, this inventory build points to a company trying to avoid the supply shortages that dogged the launch of tirzepatide, when demand outpaced manufacturing ^[1]. If Lilly succeeds, patients prescribed orforglipron once it is approved may face fewer of the stockouts and rationing that have affected injectable GLP-1 drugs.

Orforglipron is a pill, not an injection, which could matter for people who dislike needles or who have trouble accessing injectable devices. But as of this filing, the drug had not been approved by the FDA, so it was not available to patients, and its price, coverage, and final label were not yet set ^[1][2]. The size of the inventory also signals that Lilly expects very large demand: the analyst estimate of roughly $10 billion in implied sales, based only on 2024 figures, suggests the company is planning for a blockbuster launch ^[1].

The move also reflects a competitive market. Novo Nordisk was studying its own oral obesity drug candidate, amycretin, and AstraZeneca was developing an oral obesity treatment as well ^[1]. Lilly's early stockpiling suggests it wants to be first and best supplied among these oral competitors.

What happens next

Lilly was expected to report late-stage clinical trial data for orforglipron by April 2025 ^[1]. The drug's inventory build was disclosed as of a filing dated February 2025, with a company launch target of 2026 ^[1]. Reuters reporting referenced later in 2026 indicates the drug was eventually marketed under the brand name Foundayo and had captured a share of new U.S. patients on oral weight-loss drugs, though the specific dollar value of Lilly's inventory stockpile beyond the initial $548 million figure was not detailed in the sources reviewed for this article ^[1][2].